肝脏脂肪变性和心血管疾病发病率的轨迹随访 29 年。

IF 3.9 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Hepatology Research Pub Date : 2024-08-19 DOI:10.1111/hepr.14101
Ming-Whei Yu, Wan-Jung Wu, Chih-Lin Lin, Chun-Jen Liu, Wei-Ya Peng, Pin-Yu Huang, Yi-Wen Huang, Jui-Ting Hu, Hung-Chuen Chang, Jyh-Ming Liou
{"title":"肝脏脂肪变性和心血管疾病发病率的轨迹随访 29 年。","authors":"Ming-Whei Yu, Wan-Jung Wu, Chih-Lin Lin, Chun-Jen Liu, Wei-Ya Peng, Pin-Yu Huang, Yi-Wen Huang, Jui-Ting Hu, Hung-Chuen Chang, Jyh-Ming Liou","doi":"10.1111/hepr.14101","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To examine the dynamic change in hepatic steatosis status during repeated assessments over time, and its potential impact on the risk of developing cardiovascular disease (CVD).</p><p><strong>Methods: </strong>We assessed trajectories of hepatic steatosis and other metabolic disorders in 3134 middle-aged adults undergoing longitudinal assessment of ultrasonography during a pre-baseline period (1993-2009) in a population-based cohort study of liver health. Subsequently, we determined the association of hepatic steatosis trajectories with the incidence of CVD among 2185 CVD-free individuals, followed until 2021. Metabolic risk factors and cardiovascular events (including coronary heart disease and stroke) were determined through medical examination and linkage with nationwide health databases.</p><p><strong>Results: </strong>We identified three discrete trajectories of hepatic steatosis according to changing pattern over time through group-based trajectory modeling: \"stable, non-steatosis\" (n = 1298), \"intermittent\" (n = 921), and \"persistent steatosis\" (n = 915). During the pre-baseline period, hepatic steatosis trajectories were associated with trajectories of developing diabetes and hypertension, and persistent steatosis (vs. other trajectories) was associated with higher risks and rapidly progressive disease patterns. At a median 13.6 years of follow-up, 629 CVD events occurred. A persistent (vs. non-steatosis: HR 1.44, 95% CI 1.17-1.76), but not intermittent, steatosis pattern predicted the future risk of CVD, after adjustment for age, sex, smoking, and obesity. This association was independent of genetic background, and remained after accounting for pre-baseline body-mass index, other cardiometabolic risk factors, Framingham risk score, medications, and hepatic fibrosis score.</p><p><strong>Conclusions: </strong>The persistence of hepatic steatosis is associated with trajectories of metabolic disorder development and increased risk of CVD. These data have important implications for practice and further research.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":null,"pages":null},"PeriodicalIF":3.9000,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Trajectories of hepatic steatosis and incidence of cardiovascular disease over a 29-year follow-up.\",\"authors\":\"Ming-Whei Yu, Wan-Jung Wu, Chih-Lin Lin, Chun-Jen Liu, Wei-Ya Peng, Pin-Yu Huang, Yi-Wen Huang, Jui-Ting Hu, Hung-Chuen Chang, Jyh-Ming Liou\",\"doi\":\"10.1111/hepr.14101\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>To examine the dynamic change in hepatic steatosis status during repeated assessments over time, and its potential impact on the risk of developing cardiovascular disease (CVD).</p><p><strong>Methods: </strong>We assessed trajectories of hepatic steatosis and other metabolic disorders in 3134 middle-aged adults undergoing longitudinal assessment of ultrasonography during a pre-baseline period (1993-2009) in a population-based cohort study of liver health. Subsequently, we determined the association of hepatic steatosis trajectories with the incidence of CVD among 2185 CVD-free individuals, followed until 2021. Metabolic risk factors and cardiovascular events (including coronary heart disease and stroke) were determined through medical examination and linkage with nationwide health databases.</p><p><strong>Results: </strong>We identified three discrete trajectories of hepatic steatosis according to changing pattern over time through group-based trajectory modeling: \\\"stable, non-steatosis\\\" (n = 1298), \\\"intermittent\\\" (n = 921), and \\\"persistent steatosis\\\" (n = 915). During the pre-baseline period, hepatic steatosis trajectories were associated with trajectories of developing diabetes and hypertension, and persistent steatosis (vs. other trajectories) was associated with higher risks and rapidly progressive disease patterns. At a median 13.6 years of follow-up, 629 CVD events occurred. A persistent (vs. non-steatosis: HR 1.44, 95% CI 1.17-1.76), but not intermittent, steatosis pattern predicted the future risk of CVD, after adjustment for age, sex, smoking, and obesity. This association was independent of genetic background, and remained after accounting for pre-baseline body-mass index, other cardiometabolic risk factors, Framingham risk score, medications, and hepatic fibrosis score.</p><p><strong>Conclusions: </strong>The persistence of hepatic steatosis is associated with trajectories of metabolic disorder development and increased risk of CVD. These data have important implications for practice and further research.</p>\",\"PeriodicalId\":12987,\"journal\":{\"name\":\"Hepatology Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2024-08-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hepatology Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/hepr.14101\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/hepr.14101","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:研究肝脂肪变性状态在反复评估过程中的动态变化及其对心血管疾病(CVD)发病风险的潜在影响:在一项基于人群的肝脏健康队列研究中,我们评估了在基线前时期(1993-2009 年)接受超声波纵向评估的 3134 名中年人的肝脂肪变性和其他代谢紊乱的轨迹。随后,我们确定了2185名无心血管疾病患者的肝脂肪变性轨迹与心血管疾病发病率的关系,这些患者的随访将持续到2021年。代谢风险因素和心血管事件(包括冠心病和中风)是通过体检和与全国健康数据库的链接确定的:通过基于组别的轨迹模型,我们根据肝脏脂肪变性随时间变化的模式确定了三种离散的肝脏脂肪变性轨迹:"稳定的非脂肪变性"(1298 人)、"间歇性"(921 人)和 "持续性脂肪变性"(915 人)。在基线前期间,肝脏脂肪变性轨迹与糖尿病和高血压的发病轨迹相关,而持续性脂肪变性(与其他轨迹相比)与更高的风险和快速进展的疾病模式相关。在中位 13.6 年的随访中,共发生了 629 起心血管疾病事件。在对年龄、性别、吸烟和肥胖进行调整后,持续性脂肪变性(与非脂肪变性相比:HR 1.44,95% CI 1.17-1.76)而非间歇性脂肪变性模式可预测未来心血管疾病的风险。这种关联与遗传背景无关,在考虑了基线前体重指数、其他心脏代谢风险因素、弗雷明汉风险评分、药物和肝纤维化评分后,这种关联依然存在:结论:肝脏脂肪变性的持续存在与代谢紊乱的发展轨迹和心血管疾病风险的增加有关。这些数据对实践和进一步研究具有重要意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Trajectories of hepatic steatosis and incidence of cardiovascular disease over a 29-year follow-up.

Aim: To examine the dynamic change in hepatic steatosis status during repeated assessments over time, and its potential impact on the risk of developing cardiovascular disease (CVD).

Methods: We assessed trajectories of hepatic steatosis and other metabolic disorders in 3134 middle-aged adults undergoing longitudinal assessment of ultrasonography during a pre-baseline period (1993-2009) in a population-based cohort study of liver health. Subsequently, we determined the association of hepatic steatosis trajectories with the incidence of CVD among 2185 CVD-free individuals, followed until 2021. Metabolic risk factors and cardiovascular events (including coronary heart disease and stroke) were determined through medical examination and linkage with nationwide health databases.

Results: We identified three discrete trajectories of hepatic steatosis according to changing pattern over time through group-based trajectory modeling: "stable, non-steatosis" (n = 1298), "intermittent" (n = 921), and "persistent steatosis" (n = 915). During the pre-baseline period, hepatic steatosis trajectories were associated with trajectories of developing diabetes and hypertension, and persistent steatosis (vs. other trajectories) was associated with higher risks and rapidly progressive disease patterns. At a median 13.6 years of follow-up, 629 CVD events occurred. A persistent (vs. non-steatosis: HR 1.44, 95% CI 1.17-1.76), but not intermittent, steatosis pattern predicted the future risk of CVD, after adjustment for age, sex, smoking, and obesity. This association was independent of genetic background, and remained after accounting for pre-baseline body-mass index, other cardiometabolic risk factors, Framingham risk score, medications, and hepatic fibrosis score.

Conclusions: The persistence of hepatic steatosis is associated with trajectories of metabolic disorder development and increased risk of CVD. These data have important implications for practice and further research.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Hepatology Research
Hepatology Research 医学-胃肠肝病学
CiteScore
8.30
自引率
14.30%
发文量
124
审稿时长
1 months
期刊介绍: Hepatology Research (formerly International Hepatology Communications) is the official journal of the Japan Society of Hepatology, and publishes original articles, reviews and short comunications dealing with hepatology. Reviews or mini-reviews are especially welcomed from those areas within hepatology undergoing rapid changes. Short communications should contain concise definitive information.
期刊最新文献
Hepatic Mac2‐BP expression depends on liver fibrosis and inflammation due to fat accumulation in patients with metabolic dysfunction‐associated steatotic liver disease Issue Information Elevated nuclear expression of ZHX1 correlates with poor prognosis in hepatocellular carcinoma (HCC): Comparison of nuclear and cytoplasmic distribution of the ZHX family in HCC cells. Efficacy of steroid therapy for improving native liver survival after pediatric acute liver failure with immune activation. Hepatitis B surface antigen glycan isomer as a new potential biomarker in patients with hepatitis B virus infection.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1